Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy

Keyphrases

• Acute muscle Injury 33%
• Ambulation 33%
• Annexin 33%
• Annexin A1 (ANXA1) 33%
• Annexin A6 33%
• Annexin Genes 33%
• Atrogin-1 33%
• Chronic Steroid Use 33%
• Chronic Steroids 33%
• Daily Dose 33%
• Duchenne muscular Dystrophy 33%
• Ergogenic 33%
• F-box Protein 32 66%
• Forkhead Box O1 (FOXO1) 33%
• Gene Expression 33%
• Glucocorticoid Response Element 33%
• Mdx Mice 33%
• Mouse Model 33%
• Muscle Atrophy 100%
• Muscle Condition 33%
• Muscle Function 33%
• Muscle Pathology 33%
• Muscle Recovery 33%
• Muscle Repair 100%
• Muscular Dystrophy 66%
• Myofiber 33%
• Once-daily Dosing 33%
• Prednisone 33%
• Reduced Side Effects 33%
• Reinforced 33%
• Single Pulse 33%
• Steroid Treatment 100%
• Transcription Factor 33%
• Weekly Dosing 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Atrogin 1 60%
• Calphobindin II 20%
• Duchenne Muscular Dystrophy 20%
• Glucocorticoid 100%
• Lipocortin 40%
• Lipocortin 1 20%
• Mouse Model 20%
• Muscle Atrophy 100%
• Muscle Injury 20%
• Muscular Dystrophy 40%
• Prednisone 20%
• Side Effect 20%
• Steroid Treatment 60%
• Transcription Factors 20%